Paragon Bioservices Celebrates Grand Opening of its World-Class Gene Therapy Biomanufacturing Facility

Paragon Bioservices 庆祝其世界级基因治疗生物制造设施的全面开放

2019-04-12 01:35:55 CISION

本文共1368个字,阅读需4分钟

 Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization with proven expertise in gene therapy and next-generation vaccines, celebrated this morning the grand opening of its new, world-class and state-of-the-art 200,000 square-foot GMP gene therapy biomanufacturing facility in Maryland's Anne Arundel County. The event brought together state and regional political and biopharmaceutical industry leaders. Distinguished guests and speakers at the event included: "With this new and impressive commercial-scale facility, Paragon Bioservices is helping to solidify Maryland's position as a premiere location for leading-edge biomanufacturing," said Governor Larry Hogan. "Our state has long been a hub for biotechnology research and scientific talent, and this transformational project squarely places Maryland at the forefront of next-generation biotherapeutic manufacturing and personalized medicine."  The new state-of-the-art facility near Baltimore/Washington Thurgood Marshall International Airport is equipped with several 500L and 2000L single-use bioreactors for clinical through commercial material production. Paragon has GMP projects underway with more than 20 of the top 40 leading gene-therapy biopharmaceutical companies in the world. "The grand opening today of our gene therapy biomanufacturing facility was a huge moment for the Paragon team," said President and CEO Pete Buzy. "Significant time and energy have been put into making this facility a reality, and I want to thank our senior leadership team and our investment partners, Camden Partners and NewSpring Health Capital. There are only a handful of other CDMOs like Paragon in the world that can do what we do, and we are prepared to meet the manufacturing demands of the double-digit growth in gene therapy that is well under way."  Paragon is one of Maryland's largest and fastest-growing biotechnology companies in the state and is one of the leading CDMOs. The Company employs a team of 350+ at its University of Maryland, Baltimore BioPark location and now at the new commercial facility near BWI airport. Paragon anticipates growing to 500+ employees by the end of the year. "We believe that our new facility greatly adds to the attractiveness of the region from both an economic and workforce development standpoint," continued Mr. Buzy. "We're part of a unique ecosystem centralized amongst many world-class academic and government research institutions and hundreds of life science companies on the I-270 corridor and beyond." The grand opening event signals Paragon's strong commitment to meeting the demands of the emerging, high-growth gene therapy market with high-quality manufacturing to support our clients' new product approvals and commercialization. About Paragon Bioservices, Inc.Paragon Bioservices is an industry-leading, private-equity backed CDMO whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon aims to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses), and other complex biologics. For more information, please visit www.paragonbioservices.com. Corporate ContactPhilip Wills, Chief Commercial OfficerPH (410) 975-4050 Media ContactJuliette Bogus, PressComm PRPH (410) 980-5687Juliettebogus@presscommpr.com SOURCE Paragon Bioservices, Inc. Related Links http://www.paragonbioservices.com
Paragon Bioservices 是一家领先的私募股权投资支持的生物技术合同开发和制造组织,在基因治疗和下一代疫苗方面拥有成熟的专业知识。马里兰州安妮阿伦德尔县拥有世界级和先进的20万平方英尺 GMP 基因治疗生物制造设施。此次活动汇集了国家和地区政治和生物制药行业的领导者。活动的嘉宾及嘉宾包括: “凭借这一令人印象深刻的商业规模设施, Paragon Bioservices 正在帮助巩固马里兰作为前沿生物制造的首要位置,”州长拉里·霍根说。我们州长期以来一直是生物技术研究和科学人才的中心,这个转型项目将马里兰州置于下一代生物治疗药物制造和个性化医疗的前沿。这是一个很好的例子 位于巴尔的摩/华盛顿 Thurgood Marshall 国际机场附近的新的最先进的设施配备了几个500L 和2000L 的单一用途生物反应器,通过商业材料生产用于临床。Paragon 与全球40家领先的基因治疗生物制药企业中的20多家正在进行 GMP 项目。 “今天我们的基因治疗生物制造设施的盛大开幕对 Paragon 团队来说是一个巨大的时刻,”总裁兼首席执行官 PeteBuzy 说。“我们投入了大量的时间和精力,使这一设施成为现实,我要感谢我们的高级领导团队和我们的投资伙伴, Camden Partners 和 NewSpringHealth Capital 。世界上只有少数几个类似于 Paragon 的 CDMOs 能够做我们所做的事情,我们准备满足基因治疗的两位数增长的制造需求,目前正在进行中。”这是一个很好的例子 Paragon 是马里兰州最大、增长最快的生物技术公司之一,也是领先的 CDMO 之一。该公司在马里兰州大学巴尔的摩生物公园的位置雇用了一个350多人的团队,现在在 BWI 机场附近的新商业设施。Paragon 预计到今年年底将增加到500多名员工。 “我们认为,从经济和劳动力发展的角度来看,我们的新设施大大增加了该地区的吸引力,” Buzy 先生继续说。“我们是一个独特的生态系统的一部分,集中在许多世界级的学术和政府研究机构和数百个生命科学公司在 I-270走廊和更远的地方。” 这次盛大的开幕仪式标志着 Paragon 公司将以高质量的制造来满足新兴的高增长基因治疗市场的需求,以支持我们客户的新产品批准和商业化。 关于 Paragon Bioservices , Inc . Paragon Bioservices 是一家行业领先、私募股权支持的 CDMO 公司,其重点是尖端生物制药的开发和制造。Paragon 旨在与全球最好的生物技术和制药公司建立强大的客户合作伙伴关系,专注于转化技术,包括基因疗法( AAV )、下一代疫苗、肿瘤免疫疗法(溶瘤病毒)和其他复杂生物制剂。有关更多信息,请访问 www.pargonbioservices.com 。 公司联系人 Philip Wills ,首席商务官 PH (410)975-4050 媒体联系人 Juliette Bogus , PressComm PRPH (410)980-5687 Julietteboog @ prescommpr.com 巴拉圭生物服务公司。 相关链接 http://www.pargonbioservices.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文